Neurological
|
March 4, 2025

The Science Behind Rimegepant: A New Hope for Migraines

Written By
Dr. Jillian Foglesong Stabile MD, FAAFP
Medically Reviewed by
Updated On
March 10, 2025

Imagine a life free from the debilitating grip of migraines. Migraines can wreak havoc on your life, and unfortunately, they are very common. Around 16% of adults have experienced a migraine or severe headache. Migraines are one of the leading causes of disability worldwide, leading to significant economic impact in addition to its impact on the individual. 

The past several years have brought many advancements in therapy for treating migraines, including Rimegepant. These new advancements offer hope for effective relief in a population that has struggled to find reprieve from this debilitating illness. 

This article dives into what makes Rimegepant revolutionary, it’s benefits, how it works, and what patients and healthcare providers need to know.

[signup]

Understanding Rimegepant

Rimegepant is a newer medication for the treatment of migraines, but what exactly is it, and how does it work?

What is Rimegepant?

Rimegepant is marketed under the brand name Nurtec®. This medication is in a class of medications called calcitonin gene-related peptide receptor (CGRP) antagonists. Rimegepant is used to prevent migraines and is a rescue medication for breakthrough migraines. It can be used for people with or without an aura.

Rimegepant was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraines in 2020 and got its preventative indication in 2021. The European Union approved the medication for both indications in 2022. Rimegepant is the first medication to be approved for both preventive treatment and breakthrough. 

The approval of Rimegepant for migraines was the culmination of several years of research as Biohaven, the company that brought Rimegepant to market, began enrolling patients in Phase 3 clinical trials in mid-2017.

How Does Rimegepant Work?

Rimegepant is one of several CGRP receptor antagonists on the market. CGRP is a protein that can cause inflammation in the brain covering when released. CGRP receptor agonists prevent CGRP from being able to bind to their receptors, thereby decreasing inflammation.

Benefits of Rimegepant

Rimegepant has several benefits.

Efficacy in Treating Acute Migraines

A 2020 review study in Frontiers in Pharmacology found a significant improvement in pain levels from 2 hours to 48 hours after taking the medication. There was over a 50% improvement in freedom from pain when compared to placebo. 

Another study from 2024 showed Rimegepant to have greater efficacy for the most bothersome migraine symptoms when compared to Lasmiditan and Urogepant.

Convenience and Dual Use

Rimegepant is unique because in addition to its use in the treatment of acute migraine symptoms, it can also be used as a preventative medication. To prevent migraines, Rimegepant is dosed every other day. Rimegepant is currently the only medication approved by the FDA for both the prevention of migraines and the treatment of acute migraine.

Dosage and Administration

Rimegepant is dosed differently depending on whether it is taken for prevention or for an acute migraine.

Recommended Dosage

Rimegepant is administered as a 75mg oral dissolving tablet (ODT). For the prevention of migraines, you take Rimegepant every other day. An additional 3 tablets can be taken per month for acute migraine attacks. 

According to the manufacturer, 18 doses per 30 days is the maximum recommended dose. They also do not recommend taking more than 1 tablet in 24 hours.  

Tips for Effective Use

Rimegepant comes in a sealed foil packet. Don’t open the tablet until it is time to take it because it dissolves when exposed to moisture.  The medication dissolves when placed under your tongue. 

For the prevention of migraine, take it every other day or as directed by your healthcare provider. For an acute migraine, you should take the medication as soon as you have migraine symptoms. The medication works within 2 hours. 

Potential Side Effects

Like any medication, Rimegepant has potential side effects. 

Common Side Effects

The most common side effect of Rimegepant for both treatment of acute migraine and migraine prevention is nausea. Other potential side effects include:

  • Indigestion
  • Belching
  • Heartburn
  • Stomach discomfort

These are not the only side effects associated with Rimegepant, but they are the most common. These side effects don’t usually cause any long-term health problems. There is also the potential for more serious side effects, though these are rare.

Rare But Serious Risks

In addition to the more common side effects, Rimegpant has the potential to cause more serious side effects

  • Fever
  • Hives
  • Rash
  • Redness of the skin (especially the ears)
  • Fatigue
  • Weakness
  • Trouble breathing
  • Difficulty swallowing
  • Mild liver abnormalities

Fortunately, these side effects are rare. But if you experience these symptoms, talk with your healthcare provider.

Mitigating Risks

Rimegepant is generally well-tolerated and doesn’t cause significant side effects. However, it is important to monitor how you are feeling when starting a new medication. If you experience shortness of breath, difficulty swallowing, severe fatigue, hives, rashes, or redness of the skin, you should talk to your healthcare provider and seek medical attention. 

Nausea is the most common side effect and may be reduced by eating smaller meals more frequently or avoiding spicy foods. It may also be helpful to drink fluids in small amounts and adjust the timing of your dose.

Rimegepant vs. Other Migraine Medications

So, how does Rimegepant compare to other medications used to treat migraines? With the development of Rimegepant and other CGRP inhibitors, there has been an influx of new medications available to treat migraine. Let’s compare some of them.

Comparison with Triptans and Other CGRP Inhibitors

There are three primary classes of medications that are indicated to specifically treat migraines: CGRP receptor inhibitors, monoclonal antibodies, and triptans. Other medications, such as ibuprofen or acetaminophen, are sometimes used to treat migraines as well. 

[12,23,24,13,3,25,6]

CGRP receptor inhibitors work differently than triptans. While CGRP receptor inhibitors decrease inflammation by blocking the CGRP receptors, triptans dilate the arteries in the brain, inhibit certain neurotransmitters in the trigeminal nerve, and decrease the release of certain proteins from the trigeminal nerve.

Who Should Consider Rimegepant?

Rimegepant is unique among migraine treatment options because it can be used as both a preventative medication as well as a rescue medication for acute migraine attacks. People who are looking for one medication to help with both indications may want to consider this medication as an option. Rimegepant may also be an option for people who haven’t gotten relief from other medications. 

There are no official contraindications to Rimegepant other than an allergy to the medication, but people with vascular diseases may want to use the medication with caution since Rimegepant can affect the vascular system. 

[signup]

Key Takeaways

  • Rimegepant is the only migraine medication approved for both migraine prevention and treatment of acute migraine
  • Rimegepant is taken every other day for migraine prevention, and a total of 18 doses can be taken in 30 days
  • Rimegepant has very few contraindications
  • Rimegepant is generally well-tolerated with few side effects

Finding the right migraine medication can be a challenge, and it's important to consult with your healthcare provider to determine which medication is best for your unique situation. If you suffer from migraines, talk to your healthcare provider about whether Rimegepant may be appropriate to give you back your life. 

The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!
  1. Berman, G., Croop, R., Kudrow, D., Halverson, P., Lovegren, M., Thiry, A. C., Conway, C. M., Coric, V., & Lipton, R. B. (2020). Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache the Journal of Head and Face Pain, 60(8), 1734–1742. https://doi.org/10.1111/head.13930
  2. Blair, H. A. (2023). Rimegepant: A review in the acute treatment and preventive treatment of migraine. CNS Drugs, 37(3), 255–265. https://doi.org/10.1007/s40263-023-00988-8
  3. Bomhof, M., Heywood, J., Pradalier, A., Enahoro, H., Winter, P., & Hassani, H. (1998). Tolerability and Efficacy of Naratriptan Tablets with Long-Term Treatment (6 Months). Cephalalgia, 18(1), 33–37. https://doi.org/10.1046/j.1468-2982.1998.1801033.x
  4. Bryn Mawr Communications. (n.d.). Headache Horizons: The Promise of Dual Treatment for Migraine - Practical Neurology. Practical Neurology. https://practicalneurology.com/articles/2021-oct/headache-horizons-the-promise-of-dual-treatment-for-migraine
  5. Canada, M., & Canada, M. (2022, April 14). CGRP monoclonal antibodies (MABs): risks and side effects - Migraine CanadaTM. Migraine CanadaTM - Knowledge is power! https://migrainecanada.org/posts/the-migraine-tree/branches/preventive-treatments/cgrp-monoclonal-antibodies-mabs-risks-and-side-effects/
  6. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine | Neurology. (n.d.). Neurology. https://www.neurology.org/doi/10.1212/WNL.49.5.1219
  7. D, D. J. P. (2021, August 12). How do CGRP receptor antagonists work? - uses, side effects, drug names. RxList. https://www.rxlist.com/how_do_cgrp_receptor_antagonists_work/drug-class.htm
  8. Estimating the economic burden of migraine on US employers. (2020). The American Journal of Managed Care, 26(12), e403–e408. https://doi.org/10.37765/ajmc.2020.88547
  9. FDA. (2020). Highlights of prescribing information [Press release]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s006lbl.pdf
  10. Gao, B., Yang, Y., Wang, Z., Sun, Y., Chen, Z., Zhu, Y., & Wang, Z. (2020). Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Frontiers in Pharmacology, 10. https://doi.org/10.3389/fphar.2019.01577
  11. How to Take Nurtec® ODT | Nurtec® ODT (rimegepant) | Safety Info. (n.d.). https://www.nurtec.com/how-to-take-nurtec?cmp=100208237471&utm_source=GOOGLE&utm_medium=paidsearch&utm_campaign=9521187005&utm_content=882705458568&utm_term=nurtec%20treatment&gad_source=1&gclid=Cj0KCQiA_Yq-BhC9ARIsAA6fbAjJodC1x5_kfOHA4cKF-5T470vbKtZYjfoZZBhlL9p1wByU-pTaE7QaAjSAEALw_wcB&gclsrc=aw.ds
  12. Iannone, L. F., Vaghi, G., Sebastianelli, G., Casillo, F., Russo, A., Silvestro, M., Pistoia, F., Volta, G. D., Cortinovis, M., Chiarugi, A., Montisano, D. A., Prudenzano, M. P., Cevoli, S., Mampreso, E., Avino, G., Romozzi, M., Valente, M., Fasano, C., Battistini, S., . . . Doretti, A. (2025). Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). The Journal of Headache and Pain, 26(1). https://doi.org/10.1186/s10194-024-01935-8
  13. Kelman, L. (2008). Review of frovatriptan in the treatment of migraine. Neuropsychiatric Disease and Treatment, 49. https://doi.org/10.2147/ndt.s1871
  14. Laohapiboolrattana, W., Jansem, P., Anukoolwittaya, P., Roongpiboonsopit, D., Hiransuthikul, A., Pongpitakmetha, T., Thanprasertsuk, S., & Rattanawong, W. (2024). Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. The Journal of Headache and Pain, 25(1). https://doi.org/10.1186/s10194-024-01904-1
  15. Miles For Migraine. (2023, June 27). Migraine Statistics and Facts | Miles for Migraine. Miles for Migraine. https://www.milesformigraine.org/migraine-statistics-facts/
  16. Nicolas, S., & Nicolas, D. (2024, February 25). Triptans. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK554507/
  17. Nurtec ODT (rimegepant) FDA Approval History. (n.d.). Drugs.com. https://www.drugs.com/history/nurtec-odt.html
  18. Rashid, A., & Manghi, A. (2023, July 10). Calcitonin Gene-Related Peptide receptor. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK560648/
  19. Rimegepant (oral route). (2025, February 1). Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/rimegepant-oral-route/description/drg-20484237
  20. Rimegepant: MedlinePlus drug information. (n.d.). https://medlineplus.gov/druginfo/meds/a620031.html
  21. Safety Profile | Nurtec® ODT (rimegepant) | Safety Info. (n.d.). https://www.nurtec.com/side-effects
  22. Slomski, A. (2021). Oral Rimegepant Safe, Effective for migraine prevention. JAMA, 325(8), 713. https://doi.org/10.1001/jama.2021.0651
  23. Spierings, E. L. H., Gomez-Mancilla, B., Grosz, D. E., Rowland, C. R., Whaley, F. S., & Jirgens, K. J. (2001). Oral Almotriptan vs Oral Sumatriptan in the Abortive Treatment of Migraine. Archives of Neurology, 58(6), 944. https://doi.org/10.1001/archneur.58.6.944
  24. Stark, R., Dahlöf, C., Haughie, S., & Hettiarachchi, J. (2002). Efficacy, Safety and Tolerability of Oral Eletriptan in the Acute Treatment of Migraine: Results of A Phase Iii, Multicentre, Placebo-Controlled Study Across Three Attacks. Cephalalgia, 22(1), 23–32. https://doi.org/10.1046/j.1468-2982.2002.00300.x
  25. Teall, J., Tuchman, M., Cutler, N., Gross, M., Willoughby, E., Smith, B., Jiang, K., Reines, S., & Block, G. (1998). Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. a Placebo‐Controlled, Outpatient study. Headache the Journal of Head and Face Pain, 38(4), 281–287. https://doi.org/10.1046/j.1526-4610.1998.3804281.x
  26. Webdev. (2024, November 20). Medicines that matter: Biohaven’s NurtecTM drug development journey. Certara. https://www.certara.com/case-study/biohaven/
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Neurological
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

Hey practitioners! 👋 Join Dr. Akil Palanisamy for a live class, "The Tiger Protocol for Immune Health," on March 19th at 2 PM EST / 11 AM PST. Autoimmune conditions are increasingly common, yet many approaches focus primarily on symptom management. Dr. Akil Palanisamy developed the TIGER Protocol, an integrative framework designed to support immune health using factors like toxins, infections, gut health, diet, and stress. Save your spot today!